GLYCTK
protein-codingglycerate kinase
Gene summary
This locus encodes a member of the glycerate kinase type-2 family. The encoded enzyme catalyzes the phosphorylation of (R)-glycerate and may be involved in serine degradation and fructose metabolism. Decreased activity of the encoded enzyme may be associated with the disease D-glyceric aciduria. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jan 2009]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~8.2 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0009070
Submitter: ClinGen
Autosomal recessive D-glyceric aciduria was first reported in 1974 (Brandt NJ et al., PMID: 4434100); however, the causative gene and variant were not identified until 2010 (Sass JO et al., PMID: 20949629). Several patients have been described in the literature, the majority based primarily on biochemical findings without accompanying genomic data. The reported clinical spectrum is highly variable, ranging from severe, progressive infantile encephalopathy to a nearly asymptomatic condition. Subsequent investigations have provided additional insights into the etiology of symptoms described in earlier reports. For example, Swanson MA et al. (PMID: 28462797) demonstrated that the nonketotic hyperglycinemia phenotype reported by Brandt NJ et al. (PMID: 4434100) and Sass JO et al. (PMID: 20949629) was attributable to a homozygous missense variant in *AMT* (c.350C>T; p.Ser117Leu). Similarly, Kingma SDK et al. (PMID: 39619776) reported a patient whose hearing loss was attributed to a homozygous pathogenic variant in *STRC* (c.4837G>T; p.Glu1613*). These findings make it unclear whether the clinical features described across reports represent a consistent phenotype attributable to *GLYCTK*, or whether they were influenced by additional genomic findings that were not assessed in earlier studies. The most consistent phenotypic feature curated for this disease entity is the accumulation of D-glycerate in urine, and in some cases serum and cerebrospinal fluid, detected by urine organic acid analysis. To date, four variants (all frameshift) have been reported across three publications (PMID: 4434100; PMID: 20949629; PMID: 39619776) and are included in this curation. The proposed disease mechanism is loss of function, supported by in vitro functional expression studies in HEK293 cells demonstrating that mutant proteins were not expressed and lacked enzymatic activity (Sass JO et al., PMID: 20949629). In summary, there is moderate evidence supporting a gene–disease relationship between *GLYCTK* and autosomal recessive D-glyceric aciduria. This classification was approved by the ClinGen IEM GCEP at the meeting on December 12, 2025 (SOP Version 11).
Inheritance Pattern: AR
Disease ID:MONDO:0009070
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0009070
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0009070
Submitter: Labcorp Genetics (formerly Invitae)
Clinical Genomic Database (CGD)
Manifestation: Biochemical; Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to GLYCTK variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_145262.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 1 | 59 | 3 | 64 | |
| missense | 1 | 134 | 10 | 2 | 147 | |
| nonsense | 1 | 1 | 2 | |||
| start loss | 0 | |||||
| frameshift | 3 | 3 | 5 | 11 | ||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 3 | 6 | 141 | 69 | 5 | 224 |
Highest pathogenic variant AF is 0.00010161078
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_660305.2 | 4 | MANE Select | |
| Ensembl | ENSP00000389175.2 | 4 | MANE Select | |
| RefSeq | NP_001138423.1 | 3 | Standard | |
| RefSeq | NP_001424550.1 | 4 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Glycerolipid metabolism - Homo sapiens (human)
- Glycine, serine and threonine metabolism - Homo sapiens (human)
- Pentose phosphate pathway - Homo sapiens (human)
- Glyoxylate and dicarboxylate metabolism - Homo sapiens (human)
- 3-Phosphoglycerate dehydrogenase deficiency
Biological Process
- protein phosphorylation
- fructose catabolic process to hydroxyacetone phosphate and glyceraldehyde-3-phosphate
Molecular Function
- protein binding
- ATP binding
- glycerate kinase activity
Cellular Component
- cytoplasm
- mitochondrion
- Golgi apparatus
- cytosol
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000436784
- Coding exons
- 4
- Length
- 8168
- Individuals with no LoFs
- 125681
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 61
- Defined
- 125742
- p
- 0.000243
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -0.228 | 333 | 322 | 1.04 | 0.0000200 | 3298 |
| Missense (PolyPhen) | 84 | 83.288 | 1.0086 | 906 | ||
| Synonymous | -0.502 | 147 | 139 | 1.05 | 0.00000777 | 1232 |
| Loss of Function | -0.171 | 15 | 14.3 | 1.05 | 6.14e-7 | 154 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00031 | 0.00031 | rare |
| Latino/Admixed American | 0.00061 | 0.00061 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00011 | 0.00011 | rare |
| Finnish | 0.000047 | 0.000046 | rare |
| European (Non-Finnish) | 0.00021 | 0.00021 | rare |
| South Asian | 0.00026 | 0.00026 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
Recessive Scores
- pRec
- 0.186
Intolerance Scores
- LoFtool
- 0.810
- RVIS EVS
- 0.24
- RVIS percentile EVS
- 69.46
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.766
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |